Evidence map›Paper›PMID 26807597›Full record

ArticleBiochemistry2016

Distributive O-GlcNAcylation on the Highly Repetitive C-Terminal Domain of RNA Polymerase II.

Lei Lu, Dacheng Fan, Chia-Wei Hu, Matthew Worth, Zhi-Xiong Ma, Jiaoyang Jiang

Abstract read
In one paragraph

Article in Biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. A nexus of lipid andFrontiers in endocrinology · 2022
    Review
  6. Advances in chemical probing of proteinChemical Society reviews · 2021
    Review
  7. Role ofPhysiological reviews · 2021
    Review
  8. Article
  9. Review
  10. Review
  11. O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.Journal of bioenergetics and biomembranes · 2018
    Review
  12. Nutrient-DrivenFrontiers in endocrinology · 2018
    Article
  13. The emerging link between O-GlcNAcylation and neurological disorders.Cellular and molecular life sciences : CMLS · 2017
    Review
  14. Review
  15. The pol II CTD: new twists in the tail.Nature structural & molecular biology · 2016
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lei LuPharmaceutical Sciences Division, School of Pharmacy, and ‡Department of Chemistry, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
Dacheng FanPharmaceutical Sciences Division, School of Pharmacy, and ‡Department of Chemistry, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
Chia-Wei HuPharmaceutical Sciences Division, School of Pharmacy, and ‡Department of Chemistry, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
Matthew WorthPharmaceutical Sciences Division, School of Pharmacy, and ‡Department of Chemistry, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
Zhi-Xiong MaPharmaceutical Sciences Division, School of Pharmacy, and ‡Department of Chemistry, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
Jiaoyang JiangPharmaceutical Sciences Division, School of Pharmacy, and ‡Department of Chemistry, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
University of Wisconsin–Madison · US

Funding

Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
NCRR NIH HHS S10 RR029531
6 · The paper itself

Abstract

O-GlcNAcylation is a nutrient-responsive glycosylation that plays a pivotal role in transcriptional regulation. Human RNA polymerase II (Pol II) is extensively modified by O-linked N-acetylglucosamine (O-GlcNAc) on its unique C-terminal domain (CTD), which consists of 52 heptad repeats. One approach to understanding the function of glycosylated Pol II is to determine the mechanism of dynamic O-GlcNAcylation on the CTD. Here, we discovered that the Pol II CTD can be extensively O-GlcNAcylated in vitro and in cells. Efficient glycosylation requires a minimum of 20 heptad repeats of the CTD and more than half of the N-terminal domain of O-GlcNAc transferase (OGT). Under conditions of saturated sugar donor, we monitored the attachment of more than 20 residues of O-GlcNAc to the full-length CTD. Surprisingly, glycosylation on the periodic CTD follows a distributive mechanism, resulting in highly heterogeneous glycoforms. Our data suggest that initial O-GlcNAcylation can take place either on the proximal or on the distal region of the CTD, and subsequent glycosylation occurs similarly over the entire CTD with nonuniform distributions. Moreover, removal of O-GlcNAc from glycosylated CTD is also distributive and is independent of O-GlcNAcylation level. Our results suggest that O-GlcNAc cycling enzymes can employ a similar mechanism to react with other protein substrates on multiple sites. Distributive O-GlcNAcylation on Pol II provides another regulatory mechanism of transcription in response to fluctuating cellular conditions.

Indexed as

Protein Processing, Post-TranslationalAcetylglucosamineGene DeletionGlycosylationHeLa CellsHumansKineticsMolecular WeightN-AcetylglucosaminyltransferasesPeptide FragmentsPeptide MappingProtein Interaction Domains and MotifsRecombinant Fusion ProteinsRecombinant ProteinsRepetitive Sequences, Amino AcidReproducibility of ResultsAcetylglucosamineN-AcetylglucosaminyltransferasesO-GlcNAc transferasePeptide FragmentsRecombinant Fusion ProteinsRecombinant ProteinsRNA Polymerase II

Identifiers

PMID26807597
PMCPMC6314847
OpenAlexW2286730870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.